Cerebrospinal fluid biomarkers in Parkinson disease (Q38082586)

28 August 2017

title

Cerebrospinal fluid biomarkers in Parkinson disease (English)

1 reference

28 August 2017

0 references

0 references

1 reference

1

Lucilla Parnetti

1 reference

28 August 2017

Anna Castrioto

2

1 reference

28 August 2017

Davide Chiasserini

3

1 reference

28 August 2017

Emanuele Persichetti

4

1 reference

28 August 2017

Nicola Tambasco

5

1 reference

28 August 2017

Omar El-Agnaf

6

1 reference

28 August 2017

Paolo Calabresi

7

1 reference

28 August 2017

language of work or name

English

0 references

publication date

19 February 2013

1 reference

28 August 2017

published in

Nature Reviews Neurology

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

131-140

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

28 August 2017

1 reference

Preclinical biomarkers of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Changing concepts of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Problems associated with fluid biomarkers for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Interactions of Amyloidogenic Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Pathological roles of α-synuclein in neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Exploring the link between glucocerebrosidase mutations and parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Pathogenic lysosomal depletion in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Identification of two distinct synucleins from human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Mechanisms underlying altered striatal synaptic plasticity in old A53T-α synuclein overexpressing mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

alpha-Synuclein locus triplication causes Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Alpha-synuclein locus duplication as a cause of familial Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Genome-wide association study reveals genetic risk underlying Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

In vivo demonstration that alpha-synuclein oligomers are toxic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Soluble oligomers for the diagnosis of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Phosphorylated α-synuclein in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

A soluble α-synuclein construct forms a dynamic tetramer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

The epidemiology of dementia associated with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Differences in neuropathologic characteristics across the Lewy body dementia spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Amyloid-β and τ biomarkers in Parkinson's disease-dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

[11C]PIB binding in Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

CSF biomarkers in different phenotypes of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Autophagy in the Pathogenesis of Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Autophagy: process and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Mitochondrial electron-transport-chain inhibitors of complexes I and II induce autophagic cell death mediated by reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Occurrence of Parkinson's syndrome in type I Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

The risk of Parkinson's disease in type 1 Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Phenotype, diagnosis, and treatment of Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Glucocerebrosidase gene L444P mutation is a risk factor for Parkinson's disease in Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Deep brain stimulation of the globus pallidus for generalized dystonia in GM1 Type 3 gangliosidosis: technical case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Decreased expression of lysosomal alpha-galactosiase A gene in sporadic Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Biochemical premotor biomarkers for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

The Parkinson Progression Marker Initiative (PPMI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Tauopathies and synucleinopathies: Do cerebrospinal fluid β-amyloid peptides reflect disease-specific pathogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Parkinson's disease subtypes: lost in translation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

CSF α-synuclein does not differentiate between parkinsonian disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Recent advances in the understanding of the role of synaptic proteins in Alzheimer's Disease and other neurodegenerative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

CSF markers of neurodegeneration in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Neprilysin Activity in Cerebrospinal Fluid is Associated with Dementia and Amyloid-β42 Levels in Lewy Body Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Association between Parkinson's disease and glucocerebrosidase mutations in Brazil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Decreased activities of lysosomal acid alpha-D-galactosidase A in the leukocytes of sporadic Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.10

31 March 2020

1 reference

https://pubmed.ncbi.nlm.nih.gov/23419373

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

1 reference

https://pubmed.ncbi.nlm.nih.gov/23419373

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23419373

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRNEUROL.2013.10

1 reference

Dimensions Publication ID

28 August 2017

1018323087

0 references

1 reference